Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050908 | 0.95 | ADORA2B (0.90) | ADORA2BADORA1ADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL4060131 | 0.91 | ADORA2B (0.83) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4225728 | 0.91 | ADORA2B (0.83) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4051837 | 0.87 | ADORA2B (0.77) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4060045 | 0.86 | ADORA2B (0.76) | ADORA2BADORA1ADORA3ADORA2AHTR2A | |
| SCHEMBL4059576 | 0.84 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2ASMN1; SMN2 | |
| SCHEMBL4057447 | 0.83 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4232776 | 0.82 | ADORA2B (0.69) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4052195 | 0.81 | ADORA2B (0.90) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL4054171 | 0.80 | ADORA2B (0.93) | ADORA2BADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| EP-1492793-B1 | NEW-4-(PYRROLOPYRIMIDIN-6-YL)BENZENESULPHONAMIDE DERIVATIVES | ALMIRALL LAB (ES) | 2008-01-16 | — | — | EP | disclosed |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 4/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.